83 related articles for article (PubMed ID: 7546893)
1. [Contribution of biology to the therapeutic decision: cancer of the breast in 1995].
Chinot O; Romain S; Martin PM
Bull Cancer Radiother; 1995; 82(2):225-37. PubMed ID: 7546893
[No Abstract] [Full Text] [Related]
2. [Intra-tissue biological markers in cancers of the breast: current assessment].
Romain S; Spyratos F; Goussard J; Magdelenat H; Martin PM
Arch Anat Cytol Pathol; 1994; 42(5):251-61. PubMed ID: 7872816
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in breast cancer patients].
Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
[No Abstract] [Full Text] [Related]
4. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Liebert A; Quietzsch D; Beier L
Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
7. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
8. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
9. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Jänicke F; Schmitt M; Graeff H
Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300
[No Abstract] [Full Text] [Related]
10. Molecular prognostic factors for breast cancer metastasis and survival.
Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN
Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190
[TBL] [Abstract][Full Text] [Related]
11. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
12. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
[TBL] [Abstract][Full Text] [Related]
13. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
[TBL] [Abstract][Full Text] [Related]
16. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
18. Cancer is heterogeneous.
Guinebretiere JM
J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
[No Abstract] [Full Text] [Related]
19. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors].
Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA
Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
